Cited 0 times in
Recent Update on Neurosurgical Management of Brain Metastasis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장종희 | - |
dc.contributor.author | 강석구 | - |
dc.contributor.author | 유지환 | - |
dc.contributor.author | 박현호 | - |
dc.date.accessioned | 2022-12-22T02:30:28Z | - |
dc.date.available | 2022-12-22T02:30:28Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.issn | 2288-2405 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191613 | - |
dc.description.abstract | Brain metastasis (BM), classified as a secondary brain tumor, is the most common malignant central nervous system tumor whose median overall survival is approximately 6 months. However, the survival rate of patients with BMs has increased with recent advancements in immunotherapy and targeted therapy. This means that clinicians should take a more active position in the treatment paradigm that passively treats BMs. Because patients with BM are treated in a variety of clinical settings, treatment planning requires a more sophisticated decision-making process than that for other primary malignancies. Therefore, an accurate prognostic prediction is essential, for which a graded prognostic assessment that reflects next-generation sequencing can be helpful. It is also essential to understand the indications for various treatment modalities, such as surgical resection, stereotactic radiosurgery, and whole-brain radiotherapy and consider their advantages and disadvantages when choosing a treatment plan. Surgical resection serves a limited auxiliary function in BM, but it can be an essential therapeutic approach for increasing the survival rate of specific patients; therefore, this must be thoroughly recognized during the treatment process. The ultimate goal of surgical resection is maximal safe resection; to this end, neuronavigation, intraoperative neuro-electrophysiologic assessment including evoked potential, and the use of fluorescent materials could be helpful. In this review, we summarize the considerations for neurosurgical treatment in a rapidly changing treatment environment. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Brain Tumor Society | - |
dc.relation.isPartOf | Brain Tumor Research and Treatment | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Recent Update on Neurosurgical Management of Brain Metastasis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학교실) | - |
dc.contributor.googleauthor | Jihwan Yoo | - |
dc.contributor.googleauthor | Hun Ho Park | - |
dc.contributor.googleauthor | Seok-Gu Kang | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.identifier.doi | 10.14791/btrt.2022.0023 | - |
dc.contributor.localId | A03470 | - |
dc.contributor.localId | A00036 | - |
dc.contributor.localId | A05158 | - |
dc.contributor.localId | A01750 | - |
dc.relation.journalcode | J00398 | - |
dc.identifier.eissn | 2288-2413 | - |
dc.identifier.pmid | 35929114 | - |
dc.subject.keyword | Brain neoplasms | - |
dc.subject.keyword | Evoked potentials | - |
dc.subject.keyword | Fluorescein | - |
dc.subject.keyword | Neoplasm grading | - |
dc.subject.keyword | Neurosurgery | - |
dc.contributor.alternativeName | Chang, Jong Hee | - |
dc.contributor.affiliatedAuthor | 장종희 | - |
dc.contributor.affiliatedAuthor | 강석구 | - |
dc.contributor.affiliatedAuthor | 유지환 | - |
dc.contributor.affiliatedAuthor | 박현호 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 164 | - |
dc.citation.endPage | 171 | - |
dc.identifier.bibliographicCitation | Brain Tumor Research and Treatment, Vol.10(3) : 164-171, 2022-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.